Contents Chapter 1 General Introduction 12 Chapter 2 Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - A tutorial Anal Chim Acta 2019; 1080: 22‒34 24 Chapter 3 Quantification of coagulation factor VIII in human plasma with liquid chromatography tandem mass spectrometry using a selective sample purification with camelid nanobodies J Pharm Biomed Anal 2019; 175: 112781 50 Chapter 4 Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle Int J Lab Hematol 2020; 42: 819‒826 68 Chapter 5 Quantification of emicizumab by mass spectrometry in plasma of people with haemophilia A: A method validation study Res Pract Thromb Haemost 2022; 6: e12725 84 Chapter 6 Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review Clin Pharmacokinet 2021; 60: 1395‒1406 102 Chapter 7 The efficacy of the entire-vial dosing of emicizumab: real-world evidence on plasma concentrations, bleeds and drug waste Res Pract Thromb Haemost 2023; 7: e100074 124 Chapter 8 DosEmi study protocol: a phase IV, multicenter, open-label, crossover study to evaluate noninferiority of pharmacokineticguided reduced dosing compared with conventional dosing of emicizumab in persons with haemophilia A Submitted 142 Chapter 9 General Discussion 158 Chapter 10 Summary 180 Chapter 11 Nederlandse lekensamenvatting 186 Appendices About the author List of coauthors List of publications Dankwoord 194 195 198 200
RkJQdWJsaXNoZXIy MTk4NDMw